Walleye Trading’s Anika Therapeutics ANIK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q4
Sell
-5,100
Closed -$217K 5303
2021
Q3
$217K Buy
+5,100
New +$210K ﹤0.01% 3769
2021
Q2
Sell
-5,300
Closed -$216K 5109
2021
Q1
$216K Buy
5,300
+1,100
+26% +$41.7K ﹤0.01% 3533
2020
Q4
$190K Sell
4,200
-10,800
-72% -$410K ﹤0.01% 3550
2020
Q3
$531K Sell
15,000
-14,300
-49% -$517K ﹤0.01% 2192
2020
Q2
$1.1M Buy
29,300
+7,400
+34% +$244K 0.01% 1578
2020
Q1
$633K Buy
21,900
+6,700
+44% +$271K ﹤0.01% 1672
2019
Q4
$788K Buy
15,200
+8,300
+120% +$482K 0.01% 2010
2019
Q3
$379K Buy
6,900
+3,900
+130% +$200K ﹤0.01% 2395
2019
Q2
$122K Sell
3,000
-8,300
-73% -$303K ﹤0.01% 3222
2019
Q1
$342K Buy
+11,300
New +$387K ﹤0.01% 2593
2018
Q4
Sell
-1,600
Closed -$67K 4580
2018
Q3
$67K Sell
1,600
-5,300
-77% -$209K ﹤0.01% 4422
2018
Q2
$221K Buy
+6,900
New +$284K ﹤0.01% 3559

Other funds holding ANIK

Walleye Trading's ANIK Position: Q2 2021 in Review

Walleye Trading sold out of Anika Therapeutics (ANIK) in Q2 2021, closing a stake of 4,922 shares — an estimated $201K sold.

Walleye Trading first reported a position in ANIK in Q4 2015 and held it in 10 quarters. The position peaked at $359K in Q2 2018. 139 funds tracked by Wall St. Rank hold ANIK as of Q2 2021.

  • Walleye Trading reported no remaining Anika Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Walleye Trading sold 4,922 Anika Therapeutics shares in Q2 2021, an estimated $201K.
  • Walleye Trading first reported a position in Anika Therapeutics in Q4 2015 and held it in 10 quarters.
  • Walleye Trading's Anika Therapeutics position peaked at $359K in Q2 2018.
  • 139 funds tracked by Wall St. Rank held Anika Therapeutics as of Q2 2021.

Based on Walleye Trading's 13F filing for Q2 2021, filed 16 Aug 2021.